Diversify Advisory Services LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Diversify Advisory Services LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 15,872 shares of the company’s stock, valued at approximately $1,179,000.

Several other large investors have also recently made changes to their positions in the business. Royal Bank of Canada boosted its holdings in shares of TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after acquiring an additional 868 shares during the period. Goldman Sachs Group Inc. raised its position in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after acquiring an additional 86,721 shares during the period. Russell Investments Group Ltd. boosted its stake in TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after acquiring an additional 938 shares during the last quarter. Finally, M&T Bank Corp purchased a new position in TransMedics Group in the second quarter valued at about $209,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TMDX shares. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. TD Cowen reaffirmed a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC decreased their price objective on TransMedics Group from $142.00 to $106.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Price Performance

TMDX stock opened at $93.97 on Thursday. The firm has a 50 day moving average of $76.71 and a 200-day moving average of $95.63. The firm has a market capitalization of $3.25 billion, a P/E ratio of 24.16 and a beta of 1.90. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period last year, the company posted $0.92 EPS. The business’s revenue was up 20.7% on a year-over-year basis. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1.47 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.